Cargando…

ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network

BACKGROUND: Drug resistance is the primary cause of failure in the treatment of cancer. Identifying signatures of chemoresistance will help to overcome this problem. Current drug resistance studies focus on protein-coding genes and ignore non-coding RNAs (ncRNAs), rendering it a challenging task to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Haixiu, Xu, Yanjun, Shang, Desi, Shi, Hongbo, Zhang, Chunlong, Dong, Qun, Zhang, Yizheng, Bai, Ziyi, Cheng, Shujun, Li, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723624/
https://www.ncbi.nlm.nih.gov/pubmed/33313140
http://dx.doi.org/10.21037/atm-20-603
_version_ 1783620380304343040
author Yang, Haixiu
Xu, Yanjun
Shang, Desi
Shi, Hongbo
Zhang, Chunlong
Dong, Qun
Zhang, Yizheng
Bai, Ziyi
Cheng, Shujun
Li, Xia
author_facet Yang, Haixiu
Xu, Yanjun
Shang, Desi
Shi, Hongbo
Zhang, Chunlong
Dong, Qun
Zhang, Yizheng
Bai, Ziyi
Cheng, Shujun
Li, Xia
author_sort Yang, Haixiu
collection PubMed
description BACKGROUND: Drug resistance is the primary cause of failure in the treatment of cancer. Identifying signatures of chemoresistance will help to overcome this problem. Current drug resistance studies focus on protein-coding genes and ignore non-coding RNAs (ncRNAs), rendering it a challenging task to systematically identify ncRNAs involved in drug resistance. METHODS: In this study, protein-protein, miRNA-target gene, miRNA-lncRNA interactions were integrated to construct a mRNA-miRNA-lncRNA network. Then, the random walk with restart (RWR) method was extended to the network for identifying ncRNA signatures of drug resistance. The leave-one-out cross validation (LOOCV) and receiver operating characteristic curve (ROC) were used to estimate the performance of ncDRMarker. Wilcoxon rank-sum test was used to validate the identified ncRNAs in NCI-60 cancer cell lines. KEGG pathway enrichment analysis was implemented to characterize the biological function of some identified ncRNAs. RESULTS: We performed this method on ten common clinical chemotherapy drugs and analyzed the results in detail. The region beneath the ROC was up to 0.881–0.951, which did not change significantly in the incomplete network, indicating the high performance and robustness of the method. Further, we confirmed the role of the identified ncRNAs in drug resistance, i.e., miR-92a-3p, a candidate chemoresistance ncRNA of tamoxifen and paclitaxel, can significantly classify cancer cell lines into sensitive or resistant to tamoxifen (or paclitaxel). We also dissected the mRNA-miRNA-lncRNA composite network and found that some hub ncRNAs, such as miR-124-3p, were involved in resistance of multiple drugs and engaged in many significant cancer-related pathways. Lastly, we have provided a ncDRMarker platform for users to identify candidate ncRNAs of drug resistance, which is available at http://bio-bigdata.hrbmu.edu.cn/ncDRMarker/index. CONCLUSIONS: Our findings suggest that ncDRMarker is an effective computational technique for prioritizing candidate ncRNAs of drug resistance. Additionally, the identified ncRNAs could be targeted to overcome drug resistance and help realize individualized treatment.
format Online
Article
Text
id pubmed-7723624
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77236242020-12-10 ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network Yang, Haixiu Xu, Yanjun Shang, Desi Shi, Hongbo Zhang, Chunlong Dong, Qun Zhang, Yizheng Bai, Ziyi Cheng, Shujun Li, Xia Ann Transl Med Original Article BACKGROUND: Drug resistance is the primary cause of failure in the treatment of cancer. Identifying signatures of chemoresistance will help to overcome this problem. Current drug resistance studies focus on protein-coding genes and ignore non-coding RNAs (ncRNAs), rendering it a challenging task to systematically identify ncRNAs involved in drug resistance. METHODS: In this study, protein-protein, miRNA-target gene, miRNA-lncRNA interactions were integrated to construct a mRNA-miRNA-lncRNA network. Then, the random walk with restart (RWR) method was extended to the network for identifying ncRNA signatures of drug resistance. The leave-one-out cross validation (LOOCV) and receiver operating characteristic curve (ROC) were used to estimate the performance of ncDRMarker. Wilcoxon rank-sum test was used to validate the identified ncRNAs in NCI-60 cancer cell lines. KEGG pathway enrichment analysis was implemented to characterize the biological function of some identified ncRNAs. RESULTS: We performed this method on ten common clinical chemotherapy drugs and analyzed the results in detail. The region beneath the ROC was up to 0.881–0.951, which did not change significantly in the incomplete network, indicating the high performance and robustness of the method. Further, we confirmed the role of the identified ncRNAs in drug resistance, i.e., miR-92a-3p, a candidate chemoresistance ncRNA of tamoxifen and paclitaxel, can significantly classify cancer cell lines into sensitive or resistant to tamoxifen (or paclitaxel). We also dissected the mRNA-miRNA-lncRNA composite network and found that some hub ncRNAs, such as miR-124-3p, were involved in resistance of multiple drugs and engaged in many significant cancer-related pathways. Lastly, we have provided a ncDRMarker platform for users to identify candidate ncRNAs of drug resistance, which is available at http://bio-bigdata.hrbmu.edu.cn/ncDRMarker/index. CONCLUSIONS: Our findings suggest that ncDRMarker is an effective computational technique for prioritizing candidate ncRNAs of drug resistance. Additionally, the identified ncRNAs could be targeted to overcome drug resistance and help realize individualized treatment. AME Publishing Company 2020-11 /pmc/articles/PMC7723624/ /pubmed/33313140 http://dx.doi.org/10.21037/atm-20-603 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yang, Haixiu
Xu, Yanjun
Shang, Desi
Shi, Hongbo
Zhang, Chunlong
Dong, Qun
Zhang, Yizheng
Bai, Ziyi
Cheng, Shujun
Li, Xia
ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network
title ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network
title_full ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network
title_fullStr ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network
title_full_unstemmed ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network
title_short ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network
title_sort ncdrmarker: a computational method for identifying non-coding rna signatures of drug resistance based on heterogeneous network
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723624/
https://www.ncbi.nlm.nih.gov/pubmed/33313140
http://dx.doi.org/10.21037/atm-20-603
work_keys_str_mv AT yanghaixiu ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT xuyanjun ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT shangdesi ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT shihongbo ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT zhangchunlong ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT dongqun ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT zhangyizheng ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT baiziyi ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT chengshujun ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork
AT lixia ncdrmarkeracomputationalmethodforidentifyingnoncodingrnasignaturesofdrugresistancebasedonheterogeneousnetwork